Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nogapendekin alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nogapendekin alfa overview
Nogapendekin alfa (ALT-803) is under development for the treatment of non-muscle invasive bladder cancer (NMIBC), non-small cell lung cancer, squamous non-small cell lung carcinoma, metastatic, pancreatic cancer, primary peritoneal cancer, ovarian cancer, fallopian tube cancer, hepatocellular carcinoma, metastatic colorectal cancer, gastric cancer, cervical cancer, renal cell carcinoma, metastatic melanoma, squamous cell head and neck carcinoma, urothelial carcinoma, Merkle cell carcinoma, small cell lung cancer, HIV infections, gastroesophageal (GE) junction carcinomas, adenocarcinoma of the gastroesophageal junction, hereditary nonpolyposis colon cancer (lynch syndrome), recurrent glioblastoma multiforme, gliosarcoma, metastatic castration resistant prostate cancer, triple-negative breast cancer (TNBC), coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and relapsed or refractory non-Hodgkin lymphoma. It is administered through parenteral, intravesical, intravenous, intraperitoneal and subcutaneous route and acts by targeting IL2RG and IL2RB.
See Also:
The drug candidate was under development for the treatment of refractory and relapsed multiple myeloma, refractory and relapsed acute myeloid leukemia, marginal zone b-cell lymphoma, Merkel cell carcinoma, waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), B-cell non-Hodgkin lymphoma, chronic myelocytic leukemia (CML), follicular lymphoma and myelodysplastic syndrome.
ImmunityBio overview
ImmunityBio, a subsidiary of NantWorks LLC, is a clinical-stage biotechnology company developing therapies for therapies for cancer and infectious diseases. The company product pipeline includes anktiva + BCG, anktiva + keytruda (pembrolizumab), aldox + anktiva + PD-L1 t-hank, anktiva + tri-ad5 vaccines, anktiva + bevacizumab + PD-L1 t-hank, anktiva + IBRX-042 vaccination, anktiva + M-ceNK and anktiva + CD19 t-haNK. ImmunityBio pipeline candidates treat bladder cancer, lung cancer, lynch syndrome, pancreatic cancer, glioblastoma, HPV, advanced Solid tumors, non-hodgkin lymphoma and HIV. The company operates in Italy, South Korea and the US. ImmunityBio is headquartered in San Diego, California, the US.
For a complete picture of Nogapendekin alfa’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
